What is the recommended acute treatment for a patient with gout affecting the first metatarsophalangeal joint?

Acute Gout Management for First Metatarsophalangeal Joint

For a patient with acute gout affecting the first metatarsophalangeal joint, initiate treatment within 12 hours of symptom onset using oral prednisone 30–35 mg daily for 5 days, full-dose NSAIDs (e.g., naproxen 500 mg twice daily), or colchicine (1.2 mg immediately followed by 0.6 mg one hour later), with the choice guided by renal function, cardiovascular status, and drug interactions. 1, 2, 3

Critical Timing Window

• Treatment must begin within 12–24 hours of symptom onset; this is the single most important determinant of success, more critical than which specific agent you choose. 1, 2, 3
• Colchicine achieves maximum efficacy when started within 12 hours and should not be initiated after 36 hours from symptom onset because effectiveness drops dramatically. 1, 2
• Delaying any anti-inflammatory therapy beyond 24 hours markedly reduces the likelihood of rapid pain resolution. 1, 3

First-Line Treatment Selection Algorithm

Choose Oral Prednisone 30–35 mg Daily for 5 Days When:

• eGFR < 30 mL/min (severe renal impairment) 1, 3
• Heart failure or uncontrolled hypertension present 2, 3
• Active or recent peptic ulcer disease or GI bleeding 1, 3
• Cirrhosis or hepatic impairment 1, 3
• Patient is on anticoagulation therapy 1, 3
• No taper is required for a 5-day course in uncomplicated monoarticular attacks. 3
• Prednisone provides efficacy equivalent to NSAIDs but with a lower adverse-event rate (27% vs 63%). 3

Choose Colchicine 1.2 mg Then 0.6 mg One Hour Later When:

• Symptom onset was ≤12 hours ago 1, 2
• No severe renal impairment (CrCl ≥30 mL/min) 1, 2
• Patient is NOT receiving strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, erythromycin, cyclosporine, ketoconazole, ritonavir, verapamil) 1, 2
• After the initial 1.8 mg loading dose, wait 12 hours then resume 0.6 mg once or twice daily until the attack resolves. 1
• This low-dose regimen achieves ≥50% pain reduction with a number-needed-to-treat of 3–5 and causes significantly fewer GI side effects (23% diarrhea) compared to obsolete high-dose regimens (77% diarrhea). 1

Choose Full-Dose NSAIDs (e.g., Naproxen 500 mg Twice Daily, Indomethacin 50 mg Three Times Daily) When:

• No renal impairment (eGFR ≥30 mL/min) 1, 3
• No cardiovascular disease or heart failure 1, 3
• No GI contraindications (add a proton pump inhibitor if any GI risk factors exist) 1, 3
• No uncontrolled hypertension 1, 3
• Continue NSAIDs at full dose throughout the entire attack without early tapering. 1, 3
• No single NSAID is more effective than others; selection should be based on availability and patient tolerance. 1

Intra-Articular Corticosteroid Injection for Monoarticular Gout

• For involvement of the first MTP joint alone, intra-articular triamcinolone acetonide 20–30 mg is highly effective and provides targeted relief with minimal systemic exposure. 1, 3, 4
• Ultrasound-guided injection improves accuracy and safety, with mean pain reduction of 48 mm on a visual analog scale within 48 hours and no adverse events reported. 4
• This approach is particularly valuable when oral agents are contraindicated or when rapid, localized control is desired. 1, 3

Absolute Contraindications to Avoid Fatal Toxicity

• Never prescribe colchicine to patients with severe renal impairment (CrCl <30 mL/min) or those receiving strong CYP3A4/P-glycoprotein inhibitors, especially when any renal or hepatic impairment co-exists—this combination can cause fatal toxicity. 1, 2, 3
• NSAIDs are contraindicated in severe renal impairment (eGFR <30 mL/min), heart failure, cirrhosis, active peptic ulcer disease, and in patients on anticoagulation. 1, 3

Management of Existing Urate-Lowering Therapy

• Do NOT discontinue allopurinol or febuxostat during an acute gout flare if the patient is already on these medications; stopping worsens the flare and hampers long-term control. 1, 2, 3
• Treat the acute flare separately while continuing the urate-lowering therapy uninterrupted. 1, 2

When to Initiate Long-Term Urate-Lowering Therapy

• After the acute flare has completely resolved, consider starting allopurinol 100 mg daily (or 50 mg daily if CrCl 30–50 mL/min) if the patient has ≥2 gout attacks per year, tophi, radiographic joint damage, chronic kidney disease stage ≥3, or serum urate >9 mg/dL. 1, 5, 6
• Mandatory colchicine prophylaxis 0.6 mg once or twice daily must be started concurrently with allopurinol and continued for at least 6 months to prevent treatment-induced flares. 1, 2, 5
• Titrate allopurinol upward by 100 mg every 2–4 weeks until serum urate falls below 6 mg/dL. 1, 5

Common Pitfalls to Avoid

• Do not delay treatment beyond 12–24 hours; effectiveness declines sharply. 1, 2, 3
• Do not start colchicine after 36 hours from symptom onset; efficacy drops dramatically. 1, 2
• Do not use obsolete high-dose colchicine regimens (0.5 mg every 2 hours); they cause severe diarrhea without added benefit. 1
• Do not taper NSAIDs early; maintain full dose throughout the attack. 1, 3
• Do not combine colchicine with strong CYP3A4/P-gp inhibitors in patients with any renal or hepatic impairment due to fatal toxicity risk. 1, 2, 3
• Do not stop urate-lowering therapy during an acute flare if the patient is already on it. 1, 2, 3

Adjunctive Measures

• Apply topical ice to the affected first MTP joint to provide additional symptomatic relief. 2, 3
• Advise limiting alcohol (especially beer), purine-rich foods (organ meats, shellfish), and high-fructose corn syrup. 2, 5, 7
• Encourage weight loss in overweight or obese patients to reduce gout burden. 2, 3, 5